Noninferiority of S-1 to UFT/LV as adjuvant chemotherapy for stage III colon cancer: A randomized phase III trial (ACTS-CC).
Yoshihiko Nakamoto
No relevant relationships to disclose
Megumi Ishiguro
Consultant or Advisory Role - Bristol-Myers Squibb; Merck Serono; Taiho Pharmaceutical
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult Honsha
Motoki Yoshida
Honoraria - Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical; Takeda
Koji Ikejiri
Research Funding - Taiho Pharmaceutical
Izumi Mochizuki
No relevant relationships to disclose
Hidetaka Mochizuki
Honoraria - Otsuka; Taiho Pharmaceutical
Research Funding - Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Kenjiro Kotake
Honoraria - Taiho Pharmaceutical; Takeda
Shingo Kameoka
Honoraria - Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical; Takeda
Keiichi Takahashi
Honoraria - Taiho Pharmaceutical; Takeda
Toshiaki Watanabe
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Masahiko Watanabe
No relevant relationships to disclose
Narikazu Boku
Honoraria - Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical
Naohiro Tomita
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
Yoshihiro Matsubara
No relevant relationships to disclose
Kenichi Sugihara
Consultant or Advisory Role - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kaken Pharmaceutical; Kyowa Hakko Kirin; Merck Serono; Ono Pharmaceutical ; Otsuka; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Wyeth; Yakult Honsha